Overview: HLA-DR2 Typing TestIntroduction: The HLA-DR2 Typing Test detects HLA-DR2 antigen to assess autoimmune or transplant risk, aiding compatibility. Following 2023 ASHI guidelines, it uses PCR for high specificity, supporting transplant screening. This test is critical for guiding transplant decisions, evaluating autoimmune risks, and improving outcomes in molecular pathology for patients with suspected autoimmune diseases or undergoing transplantation.
Other Names: HLA-DR2 Assay, HLA-DR2 Antigen Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HLA typing began in the 1960s with transplant immunology. PCR-based HLA-DR2 typing improved in the 2000s, enhancing autoimmune and transplant assessment.
Purpose: Assesses HLA-DR2 for autoimmune or transplant compatibility, guides treatment or organ matching, and evaluates risk in patients.
Test Parameters: 1. HLA-DR2 Antigen
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report history of autoimmune diseases, transplants, or family history of HLA-related conditions.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document history of autoimmune diseases, transplants, or family history of HLA-related conditions. Include current medications and prior transplant history.
Consent: Written consent required, detailing the tests purpose, compatibility or autoimmune implications, and potential need for treatment or transplant planning.
Procedural Considerations: Uses PCR to detect HLA-DR2 antigen. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for autoimmune or transplant assessment.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low DNA quality may impact typing accuracy.
Clinical Significance: Positive HLA-DR2 indicates autoimmune risk (e.g., multiple sclerosis) or transplant compatibility, guiding treatment or transplant decisions. Negative results may require alternative HLA typing.
Specialist Consultation: Consult a rheumatologist or transplant immunologist for result interpretation and planning.
Additional Supporting Tests: HLA-DQ, anti-nuclear antibodies, or antibody screening to assess autoimmune or transplant compatibility.
Test Limitations: Limited to HLA-DR2; other HLA loci may need testing. Clinical correlation is needed.
References: ASHI HLA Guidelines, 2023; Human Immunology, Tait BD, 2022.
